Stock Update (NASDAQ:GILD): Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF)-Based Single Tablet Regimen for HIV

[Business Wire] – Gilead Sciences, Inc. today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for an investigational, once-daily single tablet regimen containing elvitegravir 150 . . . → Read More: Stock Update (NASDAQ:GILD): Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF)-Based Single Tablet Regimen for HIV Similar Articles: Company Update: Gilead Sciences Inc (NASDAQ:GILD) – U.S. FDA approves Gilead’s $94,500 hepatitis C drug Market Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead signs hepatitis C pact to cut drug cost for poor Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen submits U.S. application to sell cholesterol-fighting drug